[go: up one dir, main page]

ZA200802339B - Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists - Google Patents

Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists

Info

Publication number
ZA200802339B
ZA200802339B ZA200802339A ZA200802339A ZA200802339B ZA 200802339 B ZA200802339 B ZA 200802339B ZA 200802339 A ZA200802339 A ZA 200802339A ZA 200802339 A ZA200802339 A ZA 200802339A ZA 200802339 B ZA200802339 B ZA 200802339B
Authority
ZA
South Africa
Prior art keywords
indol
carbonyl
receptor antagonists
vasopressin receptor
azaspiro derivatives
Prior art date
Application number
ZA200802339A
Other languages
English (en)
Inventor
Bissantz Caterina
Grundschober Christophe
Ratni Hasane
Rogers-Evans Mark
Schnider Patrick
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200802339B publication Critical patent/ZA200802339B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200802339A 2005-09-28 2008-03-12 Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists ZA200802339B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05108966 2005-09-28

Publications (1)

Publication Number Publication Date
ZA200802339B true ZA200802339B (en) 2009-10-28

Family

ID=37156049

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200802339A ZA200802339B (en) 2005-09-28 2008-03-12 Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists

Country Status (17)

Country Link
US (1) US7790752B2 (xx)
EP (1) EP1931680B1 (xx)
JP (1) JP4908513B2 (xx)
KR (1) KR101018934B1 (xx)
CN (1) CN101273046B (xx)
AR (1) AR057136A1 (xx)
AT (1) ATE488519T1 (xx)
AU (1) AU2006298828B2 (xx)
BR (1) BRPI0616618A2 (xx)
CA (1) CA2623715A1 (xx)
DE (1) DE602006018334D1 (xx)
ES (1) ES2354909T3 (xx)
IL (1) IL189981A (xx)
RU (1) RU2418801C2 (xx)
TW (1) TWI327571B (xx)
WO (1) WO2007039438A1 (xx)
ZA (1) ZA200802339B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
DE602007007512D1 (de) * 2006-12-08 2010-08-12 Hoffmann La Roche Als via-rezeptor-antagonisten verwendbare indole
CN101838269B (zh) * 2009-03-18 2012-09-26 中国人民解放军军事医学科学院毒物药物研究所 1,3,8-三氮杂-螺[4.5]癸烷-4-酮类化合物及其医药用途
JO3109B1 (ar) * 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
WO2017005583A1 (en) * 2015-07-03 2017-01-12 F. Hoffmann-La Roche Ag Triaza-spirodecanones as ddr1 inhibitors
EP3414247B1 (en) 2016-02-08 2021-04-21 F. Hoffmann-La Roche AG Spiroindolinones as ddr1 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769578B2 (ja) * 1989-10-13 1998-06-25 大塚製薬株式会社 バソプレシン拮抗剤
JP2002515891A (ja) * 1997-12-19 2002-05-28 スミスクライン・ビーチャム・コーポレイション 新規なピペリジン含有化合物
HU225703B1 (en) * 1999-07-15 2007-06-28 Sanofi Aventis Process for producing spiro[cis-4-(betha-hydroxy-ethyloxi)-cyclohexane-[3h]indole]-2'[1'h]-one derivatives
US6150365A (en) * 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
EA009369B1 (ru) * 2002-09-09 2007-12-28 Янссен Фармацевтика, Н.В. Производные гидроксизамещенного 1,3,8-триазинспиро[4,5]декан-4-она, полезные для лечения расстройств, опосредованных orl-рецептором
US20080287478A1 (en) * 2003-05-23 2008-11-20 Lars Bo Laurenborg Hansen Nociceptin Analogues and Uses Thereof
US7745630B2 (en) * 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
PL1904477T3 (pl) * 2005-07-14 2009-07-31 Hoffmann La Roche Pochodne indolo-3-karbonylo-spiro-piperydyny jako antagoniści receptora V1a
US7351706B2 (en) * 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
RU2009119393A (ru) * 2006-12-07 2011-01-20 Ф. Хоффманн-Ля Рош Аг (Ch) Производные спиропиперидина

Also Published As

Publication number Publication date
ATE488519T1 (de) 2010-12-15
BRPI0616618A2 (pt) 2011-06-28
IL189981A (en) 2012-09-24
US20070072888A1 (en) 2007-03-29
TW200804392A (en) 2008-01-16
CN101273046A (zh) 2008-09-24
CN101273046B (zh) 2011-05-25
KR20080049780A (ko) 2008-06-04
EP1931680B1 (en) 2010-11-17
IL189981A0 (en) 2008-08-07
JP2009510010A (ja) 2009-03-12
DE602006018334D1 (de) 2010-12-30
EP1931680A1 (en) 2008-06-18
AU2006298828B2 (en) 2011-12-01
AR057136A1 (es) 2007-11-21
CA2623715A1 (en) 2007-04-12
ES2354909T3 (es) 2011-03-21
AU2006298828A1 (en) 2007-04-12
RU2008110409A (ru) 2009-11-10
JP4908513B2 (ja) 2012-04-04
RU2418801C2 (ru) 2011-05-20
WO2007039438A1 (en) 2007-04-12
KR101018934B1 (ko) 2011-03-02
US7790752B2 (en) 2010-09-07
TWI327571B (en) 2010-07-21

Similar Documents

Publication Publication Date Title
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
TWI318206B (en) Histamine-3 receptor antagonists
ZA200803811B (en) Neuropolin antagonists
IL202561A0 (en) Benzazepine derivatives useful as vasopressin antagonists
IL187424A0 (en) C5a RECEPTOR ANTAGONISTS
IL184816A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
ZA200709147B (en) Pyrimidindione derivatives as prokineticin 2 receptor antagonists
ZA200801432B (en) Carboxamide derivatives as muscarinic receptor antagonists
IL184278A0 (en) C5a RECEPTOR ANTAGONISTS
ZA200806065B (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
AP2007004047A0 (en) Substituted triazole derivatives as oxtocin antagonists
AP2008004441A0 (en) Piperdin-4-ylpyrazin-2-ylamine derivatives as fastdissociating dopamine 2 receptor antagonists
ZA200904479B (en) Nitroderivatives as angiotensin II receptor antagonists
EP1874302A4 (en) ANTAGONISTS OF ANGIOTENSIN II RECEPTORS
ZA200802339B (en) Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
PL1912976T3 (pl) Pochodne indol-3-ilokarbonylopiperydynobenzoimidazolu jako antagoniści receptora V1a
IL185640A0 (en) Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
HU0501169D0 (en) New phenantridine derivatives as selective bradykinin b1 receptor antagonists
AP2008004537A0 (en) Muscarinic receptor antagonists
GB0525029D0 (en) Receptor Antagonist
ZA200806223B (en) Muscarinic receptor antagonists
ZA200800516B (en) Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as V1a receptor antagonists
GB0516617D0 (en) EP2 Receptor antagonists